EyePoint Pharmaceuticals, Inc. (EYPT) vs Fate Therapeutics, Inc. (FATE)
A side-by-side comparison of EyePoint Pharmaceuticals, Inc. and Fate Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EYPT
EyePoint Pharmaceuticals, Inc.
$3.14HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
FATE
Fate Therapeutics, Inc.
$2.33HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — EYPT vs FATE
growth of $100 · dividends reinvested · last 10yEYPT -89.5% (-20.2%/yr)FATE -18.2% (-2.0%/yr)FATE compounded faster over this window
Log scale — wide-divergence pair
EYPT FATE
EYPT vs FATE: by the numbers
- •FATE is the larger company ($271M vs $263M market cap).
- •Both run net losses; FATE's is the smaller (-1941.09% vs -10994.73% net margin).
- •Both shrank revenue over the past five years; FATE's decline was smaller (-32.98% vs -41.05% CAGR).
Metrics side by side
Valuation
| Metric | EYPT | FATE |
|---|---|---|
| P/S ratio | 94.44 | 41.82 |
| P/B ratio | 1.58 | 1.77 |
Profitability
| Metric | EYPT | FATE |
|---|---|---|
| Gross margin | 93.41% | -94.12% |
| Operating margin | -775.98% | -2222.45% |
| Net margin | -10994.73% | -1941.09% |
| ROE | -184.27% | -82.12% |
| ROIC | -170.19% | -58.72% |
Growth (annualized)
| Metric | EYPT | FATE |
|---|---|---|
| Revenue CAGR (5Y) | -41.05% | -32.98% |
| Total return CAGR (5Y) | -21.68% | -46.86% |
Frequently asked
- Which has grown faster, EYPT or FATE?
- Neither grew: over the past five years both shrank revenue, with FATE's decline the smaller — EYPT at a -41.05% CAGR versus FATE at -32.98%.
- How have EYPT and FATE total returns compared?
- Over the past 10 years, EYPT delivered -20.02% and FATE delivered -2.31% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.